Variables | Mean | SD | Median | Range |
---|---|---|---|---|
Age (years) | 49.4 | 11.6 | 47.0 | 30.0–82.0 |
Baseline tumor size (cm) | 3.9 | 1.9 | 3.4 | 1.2–12.0 |
T1 | 21 | 10.3 | 5.9–14.7 | |
Clinical tumor stage | T2 | 147 | 72.1 | 65.7–78.5 |
T3 | 34 | 16.7 | 11.3–22.0 | |
T4 | 2 | 0.9 | 0.1–3.5 | |
Histological type | IDC | 196 | 96.1 | 93.2–99.0 |
ILC | 8 | 3.9 | 1.0–6.8 | |
low-medium | 60 | 30.0 | 23.4–36.6 | |
Histological grade | high | 140 | 70.0 | 63.4–76.6 |
NA | 4 | |||
Hormonal receptor status | positive | 122 | 59.8 | 52.8–66.8 |
negative | 82 | 40.2 | 33.2–47.2 | |
HER2 status | positive | 75 | 36.8 | 29.9–43.6 |
negative | 129 | 63.2 | 56.4–70.1 | |
luminal B/HER2- | 77 | 37.7 | 30.8–44.6 | |
luminal B/HER2+ | 45 | 22.1 | 16.1–28.0 | |
Tumor subtype | HER2+ | 30 | 14.7 | 9.6–19.8 |
triple negative | 52 | 25.5 | 19.3–31.7 | |
Baseline axillary status | positive | 113 | 55.4 | 48.3–62.5 |
negative | 91 | 44.6 | 37.5–51.7 |
S (%) | SP (%) | PPV (%) | NPV (%) | ACC (%) | |
---|---|---|---|---|---|
62.5 | 83.3 | 84.3 | 60.9 | 71.1 | |
64.2 | 100.0 | 100.0 | 29.4 | 68.8 | |
53.8 | 89.5 | 87.5 | 58.6 | 68.9 | |
42.9 | 73.9 | 33.3 | 80.9 | 66.7 | |
75.0 | 81.2 | 71.4 | 83.9 | 78.8 |
Variable | n* | Mean size discrepancy (± SD) | p | |
---|---|---|---|---|
0.668 | ||||
≤45 | 88 | 0.72 (± 0.95) | ||
>45 | 115 | 0.79 (± 1.43) | ||
≤5 | 167 | 0.62 (± 0.87) | ||
>5 | 36 | 1.39 (± 2.18) | ||
0.347 | ||||
IDC | 195 | 0.71 (± 1.02) | ||
ILC | 8 | 2.05 (± 3.75) | ||
Low-medium | 60 | 1.25 (± 1.82) | ||
high | 139 | 0.55 (± 0.82) | ||
0.059 | ||||
positive | 121 | 0.90 (± 1.38) | ||
negative | 82 | 0.56 (± 0.97) | ||
0.956 | ||||
positive | 74 | 0.75 (± 1.13) | ||
negative | 129 | 0.76 (± 1.30) | ||
0.679 | 0.192 | 0.001 | 0.300–1.058 | |
0.214 | 0.181 | 0.239 | -0.143–0.570 | |
0.872 | 0.217 | <0.001 | 0.443–1.301 |